Researchers have developed a blood test able to detect more than 50 types of cancer that is accurate enough to be used nationally as a multi-cancer screening test in those at higher risk of the disease, including those aged over 50 with no symptoms.

The test involves taking a sample of blood from each patient and analysing it for DNA, known as cell-free DNA (cfDNA), shed by tumours (and other cells) into the blood. Genomic sequencing is used to detect chemical changes to the DNA (methylation) that control gene expression, and a classifier developed with machine learning (artificial intelligence) uses these results to detect abnormal methylation patterns that indicate the presence of cancer.

The third and final sub-study of the Circulating Cell-free Genome Atlas (CCGA) study, published in the Annals of Oncology, investigated the performance of the test in 2,823 people already diagnosed with cancer and 1,254 people without cancer.

The findings show that the test was able to detect cancer signals from more than 50 different types of cancer across all four cancer stages (I, II, III, IV), correctly identifying when cancer was present in 51.5% of cases. The test’s specificity was 99.5%, thus showing that it wrongly detected cancer in just 0.5% of cases.

According to the data, sensitivity of the test was 67.6% overall across stages I-III in 12 pre-specified cancers that account for two-thirds of cancer deaths in the US annually (anal, bladder, bowel, oesophageal, stomach, head and neck, liver and bile duct, lung, ovarian and pancreatic cancers, lymphoma and cancers of white blood cells such as multiple myeloma), and 40.7% overall in more than 50 cancers.

For all cancers, detection improved with each later cancer stage with a sensitivity rate of 16.8% at the early stage I, 40.4% at stage II, 77% at stage III and 90.1% at stage IV.

Research also showed that sensitivity varied by type of cancer; in solid tumours that do not have any screening options – such as oesophageal, liver and pancreatic cancers – overall sensitivity of the test was twice that for solid tumours that do have screening options, such as breast, bowel, cervical and prostate cancers: 65.6% compared to 33.7%. Overall sensitivity in cancers of the blood, such as lymphoma and myeloma, was 55.1%.

The test correctly also identified the tissue in which the cancer was located in the body in 88.7% of cases, the researchers said.

“These data add to a growing body of literature that supports the use of next-generation sequencing for the detection of cell-free DNA in blood samples as a tool for earlier detection of common cancers that account for a significant number of deaths and other health problems worldwide,” said first author of the paper, Dr Eric Klein, chairman of the Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, US.

“In addition, a screening test that requires only a simple blood draw could provide an option for communities that have poor access to medical facilities. I’m excited about the potential impact this approach will have on public health.”

Reference:
https://www.pharmatimes.com/news/blood_test_can_detect_more_than_50_types_of_cancer_1372224

More News
Why US is pushing India to restart Covid vaccine exports
News · 16/09/2021

The United States has been pushing India to restart vaccine exports as it looks to stem the global spread of the Covid pandemic.

READ MORE
Quess Corp launches new vertical to transform healthcare services in India
News · 01/09/2021

Quess Corp, India’s leading business services provider, announced the launch of its new healthcare vertical to address the shortage of healthcare professionals.

READ MORE
China’s Golden Week to trigger new round of void sailings
News · 01/09/2021

The shippers are in for struggle yet another time, with the market buzzing in speculations of liners planning of ‘blank sailing’ during China’s Golden Week holiday in early October to extract maximised profits.

READ MORE
Israel’s COVID-19 vaccine boosters show signs of taming delta variant of coronavirus
News · 01/09/2021

Less than a month into a COVID-19 vaccine booster drive, Israel is seeing signs of an impact on the country’s high infection and severe illness rates fuelled by the fast-spreading delta variant, officials and scientists say.

READ MORE
NUTRICOSMETICS: A Blooming Global Market
News · 16/08/2021

Nutricosmetic is the point at which nutrition and cosmetics meet. The term encompasses the beneficial effects on beauty resulting from consuming nutrients through the use of food supplements.

READ MORE
Amidation of Light Alkanes – High-end Derivatives directly from Natural Gas
News · 16/08/2021

At Last: Separated and Freshly Bound –
Amidation of light alkanes

READ MORE
AstraZeneca (AZ) says its COVID-19 vaccine protects against severe disease caused by variants
News · 02/08/2021

AstraZeneca (AZ) has announced that new real-world data from Canada shows its COVID-19 vaccine – Vaxzevria – was found to be highly effective after one dose against severe disease or hospitalisation caused by the Beta and Delta variants.

READ MORE
EDQM “RTEMIS” pilot project: real-time remote GMP inspections of API manufacturers
News · 02/08/2021

Interruptions to the inspection programme of the European Directorate for the Quality of Medicines & HealthCare (EDQM) due to travel restrictions – made necessary by the COVID-19 pandemic – led to the creation of a system of Real-Time Remote Inspections (RTEMIS).

READ MORE
Global supply chains buckle as virus variant and disasters strike
News · 02/08/2021

A number of recent events such as a new worldwide wave of COVID-19, natural disasters in China and Germany, a cyber attack targeting key South African ports have conspired to drive global supply chains towards breaking point, threatening the fragile flow of raw materials, parts and consumer goods, according to companies, economists and shipping specialists.

READ MORE